Assessing Thromboembolic Complications and In-Hospital Mortality and Clinical Factors Affecting Thromboembolic Complications in COVID-19 stage 3-5 ICU cases

Background: Thromboembolic (TE) complications are associated with the severity of the infection and are no less of a disease that contributes to the fatality of critically ill patients infected with COVID-19. Objective: This study aimed to investigate the prevalence of TE complications, in-hospital...

Full description

Bibliographic Details
Published in:Journal of Research in Pharmacy
Main Author: Wan Rosli W.N.M.; Ravi T.; Ming L.C.; Zulkifly H.H.
Format: Article
Language:English
Published: Marmara University 2024
Online Access:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85201800329&doi=10.29228%2fjrp.805&partnerID=40&md5=0ec5af944e63899981969362c6294d37
id 2-s2.0-85201800329
spelling 2-s2.0-85201800329
Wan Rosli W.N.M.; Ravi T.; Ming L.C.; Zulkifly H.H.
Assessing Thromboembolic Complications and In-Hospital Mortality and Clinical Factors Affecting Thromboembolic Complications in COVID-19 stage 3-5 ICU cases
2024
Journal of Research in Pharmacy
28
4
10.29228/jrp.805
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85201800329&doi=10.29228%2fjrp.805&partnerID=40&md5=0ec5af944e63899981969362c6294d37
Background: Thromboembolic (TE) complications are associated with the severity of the infection and are no less of a disease that contributes to the fatality of critically ill patients infected with COVID-19. Objective: This study aimed to investigate the prevalence of TE complications, in-hospital mortality, and risk factors among ICU patients (stage 3, 4, 5) infected with COVID-19. Methodology: In this retrospective single-center cross-sectional study, 106 severe patients referred to intensive care units (ICUs) due to COVID-19 between February 2021 and December 2022 were included. All patients received a thromboprophylaxis agent. Results: Mean (SD) age 49.81(13.27), 50.9% were male, 68.9% Malays, mean (SD) (2-12) days of ICU admission with the most coexisting comorbidities being hypertension (44.3%), diabetes mellitus (33%), and obesity (60.3%). Of 106 patients, 51 (41.9%) developed pulmonary embolism (PE) and 27.5% died despite adequate thromboprophylaxis. In total, 51 (41.9%) developed TE event during their ICU admission. Significantly higher proportions of COVID-19 patients who developed complications of PE (77.8% vs 42%; p = 0.006) died. D-dimer, fibrinogen, white cell count (WCC), and troponin were significantly greater among those with TE events. Demographics, co-morbidities, other laboratory parameters and were similar in COVID-19 patients with and without TE events. Conclusion: There is a high incidence of TE complications and in-hospital mortality in critically ill patients with COVID-19. A high level of D-dimer, fibrinogen, white cell count, and troponin were associated with in-hospital TE events. It is apparent that routine chemical thromboprophylaxis may not be sufficient to prevent TE complications in patients with severe COVID-19. © 2023 Marmara University Press.
Marmara University
26306344
English
Article
All Open Access; Gold Open Access
author Wan Rosli W.N.M.; Ravi T.; Ming L.C.; Zulkifly H.H.
spellingShingle Wan Rosli W.N.M.; Ravi T.; Ming L.C.; Zulkifly H.H.
Assessing Thromboembolic Complications and In-Hospital Mortality and Clinical Factors Affecting Thromboembolic Complications in COVID-19 stage 3-5 ICU cases
author_facet Wan Rosli W.N.M.; Ravi T.; Ming L.C.; Zulkifly H.H.
author_sort Wan Rosli W.N.M.; Ravi T.; Ming L.C.; Zulkifly H.H.
title Assessing Thromboembolic Complications and In-Hospital Mortality and Clinical Factors Affecting Thromboembolic Complications in COVID-19 stage 3-5 ICU cases
title_short Assessing Thromboembolic Complications and In-Hospital Mortality and Clinical Factors Affecting Thromboembolic Complications in COVID-19 stage 3-5 ICU cases
title_full Assessing Thromboembolic Complications and In-Hospital Mortality and Clinical Factors Affecting Thromboembolic Complications in COVID-19 stage 3-5 ICU cases
title_fullStr Assessing Thromboembolic Complications and In-Hospital Mortality and Clinical Factors Affecting Thromboembolic Complications in COVID-19 stage 3-5 ICU cases
title_full_unstemmed Assessing Thromboembolic Complications and In-Hospital Mortality and Clinical Factors Affecting Thromboembolic Complications in COVID-19 stage 3-5 ICU cases
title_sort Assessing Thromboembolic Complications and In-Hospital Mortality and Clinical Factors Affecting Thromboembolic Complications in COVID-19 stage 3-5 ICU cases
publishDate 2024
container_title Journal of Research in Pharmacy
container_volume 28
container_issue 4
doi_str_mv 10.29228/jrp.805
url https://www.scopus.com/inward/record.uri?eid=2-s2.0-85201800329&doi=10.29228%2fjrp.805&partnerID=40&md5=0ec5af944e63899981969362c6294d37
description Background: Thromboembolic (TE) complications are associated with the severity of the infection and are no less of a disease that contributes to the fatality of critically ill patients infected with COVID-19. Objective: This study aimed to investigate the prevalence of TE complications, in-hospital mortality, and risk factors among ICU patients (stage 3, 4, 5) infected with COVID-19. Methodology: In this retrospective single-center cross-sectional study, 106 severe patients referred to intensive care units (ICUs) due to COVID-19 between February 2021 and December 2022 were included. All patients received a thromboprophylaxis agent. Results: Mean (SD) age 49.81(13.27), 50.9% were male, 68.9% Malays, mean (SD) (2-12) days of ICU admission with the most coexisting comorbidities being hypertension (44.3%), diabetes mellitus (33%), and obesity (60.3%). Of 106 patients, 51 (41.9%) developed pulmonary embolism (PE) and 27.5% died despite adequate thromboprophylaxis. In total, 51 (41.9%) developed TE event during their ICU admission. Significantly higher proportions of COVID-19 patients who developed complications of PE (77.8% vs 42%; p = 0.006) died. D-dimer, fibrinogen, white cell count (WCC), and troponin were significantly greater among those with TE events. Demographics, co-morbidities, other laboratory parameters and were similar in COVID-19 patients with and without TE events. Conclusion: There is a high incidence of TE complications and in-hospital mortality in critically ill patients with COVID-19. A high level of D-dimer, fibrinogen, white cell count, and troponin were associated with in-hospital TE events. It is apparent that routine chemical thromboprophylaxis may not be sufficient to prevent TE complications in patients with severe COVID-19. © 2023 Marmara University Press.
publisher Marmara University
issn 26306344
language English
format Article
accesstype All Open Access; Gold Open Access
record_format scopus
collection Scopus
_version_ 1809678473529131008